Navigation Links
Cancer: Tumors absorb sugar for mobility
Date:7/28/2014

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness to join in an ordered set. Researchers are calling this behavior "mesenchymal," and they suspect it promotes metastasis.

At EPFL, Etienne Meylan's research team was able to demonstrate that the two observations appetite for sugar and mesenchymal behavior result from the same mechanism, at least in "non-small cell lung cancer." They also showed that the intensity of the phenomenon significantly influenced the chances of patient survival. Published in Cancer & Metabolism, this discovery opens up new potential targets for future therapies.

A useful mechanism, but put to work by cancer

Mesenchymal behavior is not in itself an anomaly. During embryonic development, some cells acquire these characteristics. In adults, a few cells retain this disposition.

"Mesenchymal behavior is a quite useful feature, but is abnormally reactivated in non-small cell lung cancer, which we studied," says Etienne Meylan.

The mesenchymal cancer cells studied by the researchers produce a protein called GLUT3. The latter serves the function of capturing glucose to activate various growth processes. This is the protein responsible for meeting the cell's need for sugar.

By artificially inducing mesenchymal behavior in cancer cells, the researchers found that the cells spontaneously produced GLUT3. This observation clearly shows that the same mechanism is at work. "This shift from one behavior to another, called epithelial-mesenchymal transition, is a highly debated issue. We have clearly established a cause and effect relationship between this transition and the glucose consumption of cancer cells," explains Mark Masin, lead author and PhD student at EPFL.

A case study confirms the results

Lung tumor cells produce widely varying amounts of GLUT3. This is because the gene is itself regulated by an element called ZEB1, and the amount of the latter is a function of many causes.

These variations in the amounts of GLUT3 seem to be a strong indicator of the aggressiveness of the tumor. By analyzing data from 450 patients with metastatic non-small cell lung cancer, researchers were able to show that the larger the quantity of GLUT3, the lower the chances of survival.

Patients were diagnosed relatively early and were followed for several years. Depending on whether they produced high or low amounts of GLUT3, their survival rates over seven years spanned almost 20%. "Our data don't permit us to conclude that the mechanism promotes metastasis, but it reinforces the assumption," says Mark Masin.

The discovery identifies a potential target for future medications. Etienne Meylan imagines, for example, a toxic molecule that could be specifically incorporated by GLUT3 to destroy the cell from within. "Protected by the blood-brain barrier, neurons that also produce GLUT3 would not be affected," says the researcher.


'/>"/>

Contact: Lionel Pousaz
lionel.pousaz@epfl.ch
41-795-597-161
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related medicine news :

1. Hormones after breast cancer: Not fuel for the fire after all?
2. Genetics of cancer: Non-coding DNA can finally be decoded
3. Technique Used in Some Hysterectomies May Help Spread Cancer: Study
4. Breast cancer: DMP is largely consistent with guidelines
5. Capturing cancer: A powerful new technique for early diagnosis
6. Cancer: The roots of evil go deep in time
7. Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
8. Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
9. Enzalutamide in prostate cancer: Hints of added benefit
10. Vandetanib in thyroid cancer: Added benefit not proven
11. Cosmetics and Beauty Products Could Cause Cancer: New Website Explores Evidence Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... WaterField Designs, an ... professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal gift ... or ballistic nylon, the Duo is smartly designed for Dad’s grooming routine. ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... 2016 , ... MinerEye today announced that it has been ... by Gartner1 Inc. , Each year, Gartner identifies new Cool Vendors in key ... and their products and services. , According to Gartner, “Gartner's Cool Vendors in ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE Media Group ... cancer, has added Cancer and Careers to its Advocacy Spotlight ... on continuing successful careers while fighting cancer. , As partners, both organizations will ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... businesses, announced today the publication of an original infographic, " Health Benefits Reimbursement ... insurance professionals understand how Zane Benefits complies with various federal regulations and reforms. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology: